Pulmonary arterial hypertension (PAH) is characterized by widespread loss of pulmonary microvasculature. Therefore we hypothesized that angiogenic gene therapy would reverse established PAH, in part restoring the lung microcirculation. Three weeks after monocrotaline (MCT) treatment, Fisher 344 rats were randomized to receive a total of either 1.5 ϫ 
Pulmonary arterial hypertension (PAH) is caused by progressive increases in pulmonary vasculature resistance leading to elevations in pulmonary arterial pressure. Idiopathic (I) PAH, a rare form of this disease with unknown etiology, has a particularly poor prognosis with a mean life expectancy of less than three years after diagnosis (1) . Although arterial vasoconstriction may play a role in some patients with PAH, the vast majority of patients with IPAH show little or no acute response to vasodilators, consistent with a dominant role of pulmonary arteriolar remodelling in the later stages of this disease (1, 2) . Present therapies for IPAH have only a modest impact on pulmonary hemodynamics (3) and there is no evidence that they result in significant improvement in the pathologic changes in the pulmonary arterial bed. Unfortunately, most patients are not diagnosed until late in the course of the disease, at which time advanced arterial narrowing and loss of the pulmonary microcirculation predominates (1) . Thus, new therapeutic approaches capable of reversing vascular structural changes and regenerating pulmonary microvasculature are needed to restore pulmonary hemodynamics in advanced PAH.
Whether vascular regeneration is indeed possible in the pulmonary circulation is controversial. Although there is extensive literature demonstrating a role for angiogenesis in systemic vascular beds, this has not been well recognized in the pulmonary circulation. When lung angiogenesis occurs in the context of tumors or abscesses, it is thought to originate solely from the bronchial circulation (4, 5) . Recently, gene transfer of angiogenic factors has been shown to be effective in preventing PAH in experimental models (6) (7) (8) , whereas the inhibition of vascular growth factor receptors has been reported to potentiate both PAH and pathologic vascular remodeling in response to chronic hypoxia (9) . These observations have led to suggestions that angiogenic factors may play a "protective role" in PAH (6) (7) (8) , but the precise mechanism of benefit remains to be fully defined. In addition to the classical angiogenic factors, such as vascular endothelial growth factor (VEGF), there is increasing evidence implicating nitric oxide (NO) as a critical mediator of angiogenesis both in vitro and in vivo (10) (11) (12) (13) (14) . NO is a potent stimulator of endothelial proliferation and migration, and endothelial NO synthase (eNOS) has been implicated as a downstream mediator of VEGF in the angiogenic cascade.
Therefore, the aim of the present study was to define the efficacy of angiogenic gene therapy with VEGF and eNOS in established PAH. We used a "reversal" model in which gene therapy was delayed until 3 wk after monocrotaline (MCT) administration, at which time PAH and the associated vascular remodelling was already well developed (5, 15) . In addition, we employed a novel microangiographic method to visualize the three-dimensional architecture of the pulmonary microcirculation to better assess the contribution of microvascular regeneration to any improvement in pulmonary hemodynamics in the different treatment groups. We now report that although both eNOS and VEGF gene transfer reduced the progression of PAH, only eNOS significantly reversed established PAH in the MCT model, at least in part by inducing the regeneration of the pulmonary microcirculation.
MATERIALS AND METHODS

Cell Isolation and Culture
Fisher 344 rats (Charles River Co., St. Constant, PQ, Canada) underwent skin biopsy, and fibroblasts (FBs) were cultured using an explant technique (8) . Cells were grown in Dulbecco's Modified Eagle Media (DMEM) with 10% FCS and 2% penicillin/streptomycin (5,000 U penicillin G sodium/ml; 5,000 g streptomycin sulfate/ml) in a humidified incubator (20% O 2 , 5% CO 2 at 37ЊC).
Fluorescent Cell Labeling
To determine the time course of cell survival after transplantation in the lung, skin fibroblasts between the fifth and ninth passages were labeled with the vital fluorescent dye, chloromethyl tretramethylrhodamine (CMTMR; Molecular Probes Inc., Eugene, OR) (16) , and injected 24 h later into the internal jugular vein of recipient rats (5 ϫ 10 5 cells). The animals were killed at 15 min, 1 d, 15 d, and 30 d after cell delivery (n ϭ 4-6/group), lungs were flash frozen in OCT compound (Sakura, Torrance, CA), and transverse sections (20 m) were taken from the basal, medial, and apical segments of both lungs. CMTMR labeled cells were quantified by fluorescent microscopy as described previously (16) .
Transfection
The full-length coding sequence of eNOS (16) and VEGF-165 (6, 16) were subcloned into the pVax-1 and the pcDNA3.1 plasmids, respectively (both from Invitrogen, Carlsbad, CA). FBs were transfected using the cationic polymer Superfect (Qiagen, Hilden, Germany) as previously described (6, 16) . The empty (null) pcDNA 3.1 vector was used as a control. After transfection, cells were trypsinized (0.25% trypsin, 1% EDTA), washed, and resuspended in phosphate-buffered saline (PBS), then divided into aliquots of 5 ϫ 10 5 cells/ml for injection.
Animal Model
Six-week-old Fisher 344 rats were assigned to one of four groups. The first group of animals received saline treatment (sham, n ϭ 29). The remaining three groups all received monocrotaline (MCT, 70-75 mg/ kg intraperitoneally; Aldrich Chemical, Milwaukee, WI) together with null-transfected fibroblast cells (FBs, n ϭ 27), MCT with eNOS-transfected FBs (n ϭ 32), or MCT with VEGF-transfected FBs (n ϭ 20). Rats were anesthetized with an intraperitoneal injection of xylazine (4.6 mg/kg) and ketamine (70 mg/kg), and the left cervical area was shaved and cleaned with 70% ethanol. The external jugular vein was catheterized with a silastic polyethylene cannula and flushed with heparinized saline (40 IU/ml). The tubing was then tunneled subcutaneously around the neck to the dorsal aspect of the animal, exiting through a small incision on the back of the neck, and sealed to the external environment with a removable plug. All incisions were closed with 3-0 interrupted absorbable sutures. Animals were then injected with MCT or saline and allowed to recover. Twenty-one days after MCT injection, the rats were anesthetized, and a 3F Millar microtip catheter was inserted via the right external jugular vein and into the right ventricle to obtain baseline measurements of right ventricular systolic pressure (RVSP) (Biopac System, Goleta, CA). Via the contralateral indwelling catheter, rats received three sequential injections of 5 ϫ 10 5 transfected FBs at 24-h intervals (total dose ϭ 1.5 ϫ 10 6 cells). The indwelling catheter was then removed, the left external jugular vein was ligated, and animals were allowed to recover. Fourteen days after the injection of transfected FBs, animals were re-anesthetized. A 3F Millar microtip catheter was re-inserted to record RVSPs. Animals were killed and the left lung inflated with OCT and cut into sections for fixation (4% paraformaldehyde-0.1% glutaraldehyde PBS solution) and for paraffin embedding, or frozen for cryostat sectioning. The right lung was snap-frozen in liquid nitrogen for RNA extraction. The heart was microdissected for the assessment of right to left ventricular plus septal weight ratio (RV/LV).
RT-PCR
Lung RNA was isolated and purified using Trizol extraction (Invitrogen). Two micrograms of RNA from each animal were reversetranscribed using the murine-moloney leukemia viral reverse-transcriptase with 0.5 ug of random hexamers (6) . An aliquot (1/10th) of the resulting cDNA was amplified by conventional PCR using the sequence-specific primers for the exogenous plasmids, peNOS or pVEGF (as shown in Table 1 ) for 30 and 34 cycles, respectively, with an annealing temperature of 62ЊC. A second aliquot of the same reverse transcription reaction was used to amplify the constitutively expressed gene GAPDH. This reaction was performed for 20 cycles with an annealing temperature of 62ЊC. Ten microliters of each 50-l PCR was run on a 1.5% agarose gel, and levels of pVEGF 165 and peNOS standardized by GADPH were observed by ethidium bromide staining.
Quantitative PCR. Real-time PCR (ABI 7900HT; Applied Biosystems, Foster City, CA) was performed for human eNOS transgene expression, as well as for the endogenous expression of eNOS, VEGF, Flk-2 (VEGFR2), and angiopoietin-1 (Ang1), using 2ϫ Taq Universal Master Mix with a dual-labeled probe: 6-FAM (6-carboxyfluorescein) and 6-TAMRA (6-carboxymethylrhodamine; both from PCR Core Reagents, Applied Biosystems). Quantification of the transcript was determined using a standard curve constructed from cDNA produced by a two-step conventional PCR reaction comprising an initial denaturation step at 95ЊC for 5 min and 18 cycles at 95ЊC (30 s), 50ЊC (45 s), and 72ЊC (45 s), followed by a final cycle at 72ЊC for 2 min. DNA content was determined by optical density and copy number was calculated using the molecular weight of the PCR product. Quantitative RT-PCR was performed in a 30-l reaction using 2 l of complementary cDNA from the original RT reaction. The standard curve and target genes were amplified using the primers shown in Table 2 . The thermal cycling conditions comprised an initial denaturation step at 95ЊC for 10 min and 40 cycles at 95ЊC for 15 s and 62ЊC for 1 min. All measurements were performed in duplicate.
Fluorescent Microangiography
At 21 or 35 d after MCT, the lungs from an additional 27 rats were prepared for fluorescent microangiography (FMA). A catheter was inserted into the pulmonary artery and the lungs flushed with heparinized PBS at 37ЊC, immediately followed by perfusion with a warmed (45ЊC) solution of 1% low-melting-point agarose (Sigma-Aldrich, Oakville, ON, Canada) containing 0.2 m yellow-green fluorescent microspheres (505 nm/515nm peak excitation and emission; Molecular Probes) at a concentration of 0.2% total solids. The agarose solution was injected until agarose could be seen flowing out of an incision in the left atrial appendage. The lungs were then fixed in 4% paraformaldehyde in PBS for 48 h at 4ЊC, and 150-to 200-m-thick sections were prepared on an oscillating blade microtome (Leica, Wetzlar, Germany). Some sections were also counterstained with the nuclear marker propidium iodide (Sigma-Aldrich) to identify viable tissue structure. Confocal optical sectioning (BioRad Radiance, Hercules, CA) was used to produce a Z stack of images spanning 150 m of section depth, and projections of Z-series images were created to demonstrate vessel architecture throughout the entire thickness of the section. A separate series of experiments were performed to assess the potential acute vasodilator effects of NO in this model. Twenty-one days after MCT, rats were treated with nitroglycerine (NTG 10 mg/kg, n ϭ 6) administered by intraperitoneal injection 15 min before killing. Lungs were then perfused with fluorescent agarose suspension as described above. Another control group (n ϭ 5) was treated in an identical fashion, but in the absence of NTG administration.
Quantitation of Fluorescence Intensity
Fluorescence intensity was assessed from three representative regions per animal by a blinded observer. In each section, a single confocal optical image was acquired at a predefined depth (10 m from the surface) using fixed gain, power, and pinhole settings, and the resultant image was analyzed for threshold intensity. A minimum intensity threshold value was determined which identified vascular architecture, and fluorescence intensity was quantified by counting all pixels above this threshold level (Image J, NIH 2002, http://rsb.info.nih.gov/ij). The region of analysis was outlined by manual tracing and its area calculated by total pixel count. Perfusion index (PI) was derived from the ratio of pixels above threshold intensity over total pixel area.
Histology/Immunohistochemistry
The degree of muscularization of small intraductal arterioles was assessed in 5-m lung cryosections taken from 7-15 rats per experimental group. Sections were fixed for 10 min with 2% phosphate-buffered paraformaldehyde, washed, and sequentially incubated with a von Willebrand Factor (vWF) rabbit polyclonal antibody (50 g/ml; DAKO, Mississauga, ON, Canada) and ␣-smooth muscle-specific actin (SMA) monoclonal antibody (28 g/ml; Sigma-Aldrich). Fluorescently conjugated secondary anti-mouse (FITC conjugate) or anti-rabbit (rhodamine conjugate) antibodies were used to localize primary antibody staining; omission of the primary antibodies was used as a negative control. Positive arterioles Ͻ 30 m in diameter as identified by vWF staining were classified as nonmuscular (NM), partially muscular (PM: at least one smooth muscle cell, but no continuous media), or fully muscular (FM: SMC around the entire arteriolar circumference). The proportion of arterioles exhibiting PM and FM were expressed as a percentage of the total vessel numbers counted from the section. Similarly, sections were stained with anti-SMA as described above, and the number of SMA-positive intra-alveolar arterioles were counted in three low-power (ϫ4) randomly chosen fields per section (n ϭ 6 rats per group). Arteriolar density was expressed as ratio of arteriolar number over the total number of alveoli in the same fields multiplied by 100 (i.e., arterioles/100 alveoli).
Statistical Analysis
Data are presented as mean Ϯ SEM. Differences between groups were assessed using ANOVA, followed by post hoc comparisons using unpaired t test. Differences within groups between the 21-and 35-d time points were assessed using a paired t test. A value of P Ͻ 0.05 was considered statistically significant. 
RESULTS
Engraftment and Persistence of Transplanted FBs
Multiple CMTMR-positive cells were seen within the pulmonary circulation 15 min after jugular injection ( Figure 1A 
Time-Course of Transgene Human eNOS and VEGF Expression
Using primers designed to selectively amplify plasmid-derived transcripts, peNOS or pVEGF was detected in all animals 14 d after receiving transfected cells (Figure 2A) , confirming persistent transgene expression in both groups. The expression of plasmid-derived eNOS RT transcript was further quantified by "real-time" PCR, and remained remarkably constant over the first 30 d after cell-based gene transfer, then gradually decreased but was still detectible 3 mo after injection ( Figure 2B , n ϭ 3/ each group).
Effect of Gene Transfer on Hemodynamic Parameters
In normal rats receiving only sham saline injections (i.e., no MCT or transfected cells), RVSP was 28. The ratio of the right ventricular to left ventricular ϩ septal weight (RV/LV) was used as a measure of right ventricular hypertrophy ( Figure 3B ). MCT treatment resulted in severe right ventricular hypertrophy, with a significant increase in RV/LV (0.43 Ϯ 0.06) in the null transfected group compared with 0.25 Ϯ 0.02 in the normal controls (P Ͻ 0.001 versus normal). RV/LV was reduced in both the peNOS-and pVEGF-treated groups (0.31 Ϯ 0.01 and 0.28 Ϯ 0.01, respectively) compared with nulltransfected animals (P Ͻ 0.05).
FMA of the Pulmonary Vasculature
FMA of the pulmonary microcirculation in normal control rats showed uniform filling of the arteriolar tree (Figure 4a) , down to the level of the alveolar capillaries. The lungs of the MCTtreated rats exhibited irregular narrowing of distal arterioles after 21 d (Figure 4b) , with abrupt occlusion of the pre-capillary arterioles (arrowheads), leading to heterogeneity of capillary perfusion. Cell-based gene transfer with eNOS resulted in a dramatic improvement in the appearance of the lung microvasculature at Day 35 after MCT (Figure 4c ), comparable to the normal control animals. In contrast, the perfusion pattern in lungs of MCT-treated animals was not improved by administration of a potent nitrovasoldilator, NTG (Figure 4h ). Moreover, there was no evidence of muscularization at the level of arteriolar disconituity of perfusion (Figure 4d) , and even at high power (Figure 4e) , there was no indication of excess cellularity associated with these lesions.
Pulmonary microvascular PI was significantly reduced in the MCT-treated lungs ( Figure 5A ) compared with the normal controls. Animals receiving eNOS gene transfer showed a marked improvement in capillary perfusion (P Ͻ 0.001 versus MCT), whereas the lungs of VEGF-treated rats showed an intermediate pattern, with significant residual regions of arteriolar-capillary discontinuity (ns versus MCT). A similar pattern was observed when the ratio of arterioles per 100 alveoli was determined for the same treatment groups ( Figure 5B ).
Arteriolar Muscularization and Remodeling
MCT-treated rats exhibited medial hypertrophy of small arteries that could easily be appreciated on light microscopic examination of hematoxylin and eosin-stained lung sections ( Figure 6A , panels a and b ). The proportion of muscularized arterioles was determined using dual fluorescent immunostaining for vWF and ␣ smooth muscle actin ( Figure 6A, panels c and d ) . In normal lungs, arterioles of Ͻ 30 m showed infrequent muscularization, with only 26.3 Ϯ 8.2% demonstrating PM and 6.5 Ϯ 3.2% with FM. In contrast, MCT-treated animals receiving the null vector showed a substantially greater proportion of small arterioles with PM or FM (P Ͻ 0.01 versus normal controls, Figure 6B ). Gene transfer with eNOS reduced the percentage of small arterioles exhibiting muscularization (P Ͻ 0.01 versus MCT-null), whereas MCT rats treated with VEGF-transfected cells demonstrated no significant decrease in the muscularization of small vessels.
Angiogenic Gene Expression
Administration of MCT alone produced a profound decrease in the endogenous expression of eNOS and a variety of angiogenic genes including VEGF, Flk-1, and Ang1 (Figure 7) . Cell-based gene transfer of eNOS partially restored the expression of these angiogenic genes, whereas VEGF had no significant effect.
DISCUSSION
The present report demonstrates that cell-based gene transfer with eNOS produced a significant improvement in established PAH in the MCT model, while restoring a more normal pattern of pulmonary microvasculature and alveolar capillary perfusion. These findings support reestablishment of pulmonary arteriolarcapillary continuity as an important mechanism for improvement of the hemodynamic abnormalities in experimental PAH, and suggest that the regeneration of pulmonary microcirculation could represent a novel treatment paradigm for this progressive and lethal disorder. The observation that angiogenic gene therapy was associated with the improvement in microvascular architecture in the MCT model has potentially important implications for the therapy of PAH since, in its advanced stages, this disease is characterized by widespread arteriolar pruning and loss of pulmonary microcirculation (1, 17) . While angiogenesis in systemic vascular beds has been well documented in models of chronic ischemia (13), there have been no prior reports demonstrating vascular regeneration in reponse to angiogenic factors in the pulmonary circulation. In conditions in which angiogenesis does occurs in the lung, such as in neoplasia, new vessels are thought to arise from the bronchial rather than the pulmonary arterial tree (4, 5, 18) . However, in the present study, microangiography of the pulmonary circulation clearly demonstrated the restoration of continuity between the distal pulmonary arterioles and the alveolar capillary bed in response to eNOS gene transfer in MCT-treated rats. At the very least this finding is consistent with the "recanalization" of pre-capillary arterioles, which likely involves migration and proliferation of the adjacent endothelial cells in reponse to stimulation with NO and VEGF.
The present report adds to the recent findings that transplantation of endothelial progenitor cells (EPCs) inhibits the progression of MCT-induced PAH in both the prevention (19, 20) and reversal models (20) . EPCs are released from the bone marrow into the circulation, homing to regions of ischemia or vascular damage, and are thought to participate directly and indirectly in angiogenesis and vascular repair (21) . Thus, the ability of EPCs to prevent PAH in this model provides further evidence supporting angiogenesis as a potentially therapeutic mechanism for PAH. Of note, EPCs alone did not produce significant improvement in established PAH (20) , and only eNOS-transfected EPCs were effective in reducing pulmonary arterial pressure and re-establishing capillary perfusion in the reversal model (20) . However, it is quite likely that eNOS enhanced the regenerative potential of these progenitor cells, possibly by upregulating the expression of angiogenic cytokines, and thus no firm conclusions can be drawn about any direct beneficial effects of eNOS gene transfer in extablished PAH from this report. In contrast, in the present study, the therapeutic benefit can be ascribed entirely to gene therapy, since transplantation of somatic fibroblasts resulted in no improvement by itself. Recently, bone marrow-derived mononuclear cells have been suggested to contribute to adverse adventitial (22) and medial remodeling (23) , and thus it is possible that angiogenic gene therapy may have advantages over the use of stem and progenitor cell therapy.
Although both eNOS and VEGF gene transfer reduced RVSP and RV remodeling at end-study compared with MCT alone, only eNOS resulted in a significant improvement in pulmonary hemodynamics in the same animals at Day 35 compared with Day 21. This greater efficacy of eNOS gene therapy compared with VEGF in reversing established PAH is intriguing and unexpected. In the prevention model, in which cell-based gene transfer was delivered at the same time as the administration of MCT, both transgenes produced very similar and near complete prevention of pulmonary hypertension and remodeling changes of the right ventricle and pulmonary arteries (6, 16) . Although we cannot exclude the possibility that the apparent difference in the reversal model may merely reflect gene dosage or a difference in potency between the two strategies, similar levels of mRNA expression were documented for both transgenes 2 wk after cell therapy. It is also possible that because of its broader range of potentially beneficial actions, the therapeutic effects of NO may extend beyond those of VEGF (24) . For example, NO has been shown both to inhibit the growth (25) , and promote apoptosis (26) , of vascular smooth muscle cell growth (VSCM), as well as inhibit platelet thrombosis (27) . Although these actions may contribute to the overall hemodynamic improvement seen in the MCT reversal model, they do not explain the increase in vascularity at the pre-capillary and capillary levels seen in eNOS-treated animals compared with null-transfected rats in the MCT reversal model.
It is being increasingly recognized that NO plays an important role in downstream signaling in response to a variety of angiogenic growth factors (10, 14) , including VEGF (11, 28, 29) . In addition, NO has been implicated in the regulation of angiogenic gene expression (30) . Indeed, eNOS gene transfer improved the endogenous expression of VEGF and other angiogenic genes to a greater extent than VEGF. This is unlikely to have been due solely to an effect of eNOS on the transfected FBs themsleves, since the mass of transplanted cells could only account for a small proportion of the overall lung transcript level. Thus, it is likely that the increase in mRNA levels of these genes, including eNOS itself, reflected an improvement in the expression profile of the lung vasculature due to paracrine effects of the transfected cells or indirectly as a result of restoration of more normal vascular structure and function.
Of particular relevance, our group has recently reported that eNOS may play a critical and previously unrecognized role in pulmonary vascular development during lung morphogenesis (31) . The lung circulation is unique in that the arterial and capillary beds develop independently (32) . Whereas the alveolar capillaries are thought to originate de novo by vasculogenesis, the arterial tree is believed to develop through sprouting angiogenesis and it is only in mid-to late gestation that these two beds fuse at the level of the pre-capillary arteriole (32) . Of note, the lung phenotype of eNOS-deficient pups, which exhibit a high rate of neonatal mortality due to respiratory distress (31), was highly reminiscent of alveolar capillary dysplasia (ACD) (33) (34) (35) , a clinical syndrome characterized by failure of arteriolar ingrowth into the alveolar septae and misalignment of pulmonary veins (34, 35) . Moreover, fluorescent microangiography of lungs from preterm fetal eNOS Ϫ/Ϫ pups revealed abnormalities in microvascular structure very similar to those of MCT-induced PAH. In particular, the demonstration of discontinuity of the distal arteriolar circulation is consistent with failure of normal fusion of the alveolar capillary bed.
This unique developmental mechanism of the pulmonary circulation may also have important implications for postnatal pulmonary vascular diseases. The distal "pre-capillary" arterioles, which are the last to form during embryonic development, may also be particularly vulnerable to injury and degeneration in disease. Normally, these vessels lack medial smooth muscle cells, which are known to stabilize and protect systemic arterioles from regression (36) , and exhibit only scant extracellular matrix. Thus, this critical vascular region may be uniquely susceptible to environmental stress, predisposing to microvascular degeneration, possibly as a consequence of endothelial apoptosis (9) . This is also consistent with the characteristic location of arteriolar occlusions at the pre-capillary level as visualized by microangiography in experimental PAH in the current study as well as in human lung tissue from PPH lungs (17) . The critical role of eNOS in lung vascular development may also partly explain the remarkable efficacy of eNOS gene transfer in reversal model of PAH compared with VEGF, since the same mechanisms by which this gene directs the fusion of the arteriolar and capillary beds during ontogeny (32) may also contribute the regeneration of this crucial junction in lung vascular disease.
Thus, in the present study gene therapy with eNOS resulted in the reversal of established experimental PAH, which was associated with regeneration of pre-capillary arteriolar continuity and reestablishment of the alveolar capillary perfusion. These observations have important implications both for the pathogenesis and treatment of pulmonary vascular disease, and suggest that angiogenic gene transfer may represent an effective therapeutic paradigm for advanced disease.
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